Pharmerging Markets 2016-2020

Published: November 2015
No. of Pages: 104
   

Market outlook of the pharmerging markets

The research analyst predicts the pharmerging markets to grow steadily at a CAGR of 13% during the forecast period. The increase in public and private healthcare insurance is the primary growth driver for this market. The governments of various pharmerging countries such as India have implemented several schemes that can be availed by patients to obtain free treatment for different diseases. Also, public and private multinational firms in collaboration with various insurance companies are providing healthcare coverage to their employees as a part of the employee welfare scheme, which is further leveraging people to seek treatment for the existing diseases.

The increase in healthcare spending by governments of pharmerging countries are expected to boost the market growth during the forecast period. Governments and pharmaceutical companies in these regions are making huge investments to improve accessibility to healthcare services, which is primarily driven by rising incomes, macroeconomic expansion, and government-supported policies and programs.

Segmentation and analysis of the pharmerging markets

  • Tier I countries (China)
  • Tier II countries (Brazil, India, and Russia)
  • Tier III countries (Poland, Argentina, Turkey, Mexico, Venezuela, Romania, Saudi Arabia, Colombia, Vietnam, South Africa, Algeria, Thailand, Indonesia, Egypt, Pakistan, Nigeria, and Ukraine)

The Tier I region (China) dominated the market during 2015, with a market share of 45%. An ageing population, increase in healthcare spending, and rise in market opportunities in suburban and rural areas are the main factors fueling the growth of the market in China.

Competitive landscape and key vendors

The pharmerging markets are highly fragmented due to the presence of numerous small and large vendors. Most of the international pharmaceutical companies are facing challenges such as price pressure, regulatory constraints, and competition from local and other international pharmaceutical companies in the pharmerging markets. The competitive environment in the market is expected to intensify with an increase in product extensions, technological innovations, and increase in mergers and acquisitions.

The leading vendors in the market are -

  • AstraZeneca
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer
  • Sanofi

Other prominent vendors in the market include Abbott Laboratories, AbbVie, Alexion Pharmaceuticals, Allergan, Amgen, Aspen, Astellas Pharma, Baxter, Bayer, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chugai Pharmaceutical, CSL Behring, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Endo Health Pharmaceuticals, F. Hoffmann-La Roche, Fresenius, Gilead, Grifols, H. Lundbeck, Hospira, Johnson & Johnson, Kyowa Hakko Kirin, Mallinckrodt Pharmaceuticals, Menarini, Mitsubishi Tanabe Pharma, Mylan, Novo Nordisk, Otsuka, Shire, STADA Arzneimittel, Sun Pharmaceutical, Takeda Pharma, Teva Pharmaceutical, UCB, and Valeant Pharmaceuticals.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2020
  • What are the key factors driving the pharmerging markets
  • What are the key market trends impacting the growth of the pharmerging markets
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the vendors in the pharmerging markets
  • Trending factors influencing the market shares of Tier I, Tier II, and Tier III countries
  • What are the key outcomes of the five forces analysis of the pharmerging markets

Pharmerging Markets 2016-2020

Table of Contents

PART 01: Executive summary
Highlights

PART 02: Scope of the report
Market overview

PART 03: Market research methodology
Research methodology
Economic indicators

PART 04: Introduction
Key market highlights

PART 05: Global pharmaceuticals market
Market size and forecast

PART 06: Pharmerging markets

PART 07: Market landscape
Market size and forecast
Five forces analysis

PART 08: Market segmentation based on geography

PART 09: Market overview of Tier I countries
China

PART 10: Market overview of Tier II countries
Brazil
Russia
India

PART 11: Market overview of Tier III countries
Market size and forecast

PART 12: Market drivers
Social and private health insurance
Increase in healthcare spending
High incidence of diseases
Impact of patent cliff on mature markets

PART 13: Impact of drivers

PART 14: Market challenges
Affordability and access
High competition
Partial regulatory policies
Price pressure

PART 15: Impact of drivers and challenges

PART 16: Market trends
Strategic alliances
Increase in generic sales
Mergers and acquisitions
Early drug launches in pharmerging markets

PART 17: Vendor landscape
Competitive scenario
AstraZeneca
GlaxoSmithKline
Merck
Novartis
Pfizer
Sanofi
Other prominent vendors

PART 18: Appendix
List of abbreviations

List of Exhibits

Exhibit 01: Global pharmaceuticals market 2015-2020 ($ billions)
Exhibit 02: Drivers, challenges, and trends in global pharmaceuticals market
Exhibit 03: Share of pharmerging markets in global pharmaceuticals market 2015
Exhibit 04: Pharmerging markets 2015-2020 ($ billions)
Exhibit 05: Shares of pharmerging markets in global pharmaceuticals market 2015-2020
Exhibit 06: Shares of Tier I, II, and III countries in pharmerging markets 2015-2020
Exhibit 07: Pharmerging market shares by country 2015
Exhibit 08: Shares of pharmerging markets in global pharmaceuticals market 2015 and 2020
Exhibit 09: Five forces analysis
Exhibit 10: Pharmerging markets by geography
Exhibit 11: Tier I: Geographical representation
Exhibit 12: Major therapy areas by drug sales 2015
Exhibit 13: Pharmaceuticals market in China 2015-2020 ($ billions)
Exhibit 14: Pharmaceuticals market in China: SWOT analysis
Exhibit 15: Geographic representation of Tier II countries
Exhibit 16: Pharmaceuticals market in Tier II countries 2015-2020 ($ billions)
Exhibit 17: Pharmaceuticals market in Brazil 2015-2020 ($ billions)
Exhibit 18: Pharmaceuticals market in Brazil: SWOT analysis
Exhibit 19: Pharmaceuticals market in Russia 2015-2020 ($ billions)
Exhibit 20: Pharmaceuticals market in Russia: SWOT analysis
Exhibit 21: Major therapy areas by drug sales 2015
Exhibit 22: Major acquisitions in pharmaceuticals sector in India
Exhibit 23: Pharmaceuticals market in India 2015-2020 ($ billions)
Exhibit 24: Pharmaceuticals market in India: SWOT analysis
Exhibit 25: Geographic representation of Tier III countries
Exhibit 26: Pharmaceuticals market in Tier III countries 2015-2020 ($ billions)
Exhibit 27: Revenue for select Tier III countries 2015 ($ billions)
Exhibit 28: Tier III countries' pharmaceuticals market: SWOT analysis
Exhibit 29: Impact of drivers
Exhibit 30: Impact of drivers and challenges
Exhibit 31: AstraZeneca: Business segmentation based on revenue 2014
Exhibit 32: AstraZeneca: Business segmentation based on revenue 2013 and 2014 ($ billions)
Exhibit 33: AstraZeneca: Geographical segmentation based on revenue 2014
Exhibit 34: AstraZeneca: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
Exhibit 35: AstraZeneca: SWOT analysis
Exhibit 36: GlaxoSmithKline: Business segmentation based on revenue 2014
Exhibit 37: GlaxoSmithKline: Business segmentation based on revenue 2013 and 2014 ($ billions)
Exhibit 38: GlaxoSmithKline: Geographical segmentation based on revenue 2014
Exhibit 39: GlaxoSmithKline: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
Exhibit 40: GlaxoSmithKline: SWOT analysis
Exhibit 41: Merck: Business segmentation based on revenue 2014
Exhibit 42: Merck: Business segmentation based on revenue 2013 and 2014 ($ billions)
Exhibit 43: Merck: Geographical segmentation based on revenue 2014
Exhibit 44: Merck: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
Exhibit 45: Merck: SWOT analysis
Exhibit 46: Novartis: Business segmentation based on revenue 2014
Exhibit 47: Novartis: Business segmentation based on revenue 2013 and 2014 ($ billions)
Exhibit 48: Novartis: Geographical segmentation based on revenue 2014
Exhibit 49: Novartis: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ millions)
Exhibit 50: Novartis :SWOT analysis
Exhibit 51: Pfizer: Business segmentation based on revenue 2014
Exhibit 52: Pfizer: Business segmentation based on revenue 2013 and 2014 ($ billions)
Exhibit 53: Pfizer: Geographical segmentation based on revenue 2014
Exhibit 54: Pfizer: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
Exhibit 55: Pfizer: SWOT analysis
Exhibit 56: Sanofi: Business segmentation based on revenue 2014
Exhibit 57: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 58: Sanofi: Geographical segmentation based on revenue 2014
Exhibit 59: Sanofi: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
Exhibit 60: Sanofi: SWOT analysis

Published By: Infiniti Research Limited
Product Code: Infiniti Research Limited9739


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we´┐Żll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest: